Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers

被引：3

作者：

Kato, Renpei ^{[1
]}

Obara, Wataru ^{[1
]}

机构：

[1] Iwate Med Univ, Dept Urol, Morioka, Iwate, Japan

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2022年 / 22卷 / 07期

关键词：

anti-PD-1/PD-L1; therapy; biomarker; renal cell carcinoma; PD-L1; expression; peripheral blood biomarkers; CIRCULATING TUMOR DNA; CHECKPOINT; EXPRESSION;

D O I：

10.1080/14737140.2022.2087631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：667 / 669

页数：3

共 50 条

[31] Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis
Yang, Yuanquan
Mori, Sherry, V
Li, Mingjia
Hinkley, Megan
Parikh, Anish B.
Collier, Katharine A.
Miah, Abdul
Yin, Ming
CANCER MEDICINE, 2022, 11 (07): : 1669 - 1677
[32] Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma
Walter, Beatriz
Gil, Sara
Xu Naizhen
Kruhlak, Michael J.
Linehan, W. Marston
Srinivasan, Ramaprasad
Merino, Maria J.
JOURNAL OF CANCER, 2020, 11 (12): : 3596 - 3603
[33] Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
Shah, Shalin
Wood, Kevin
Labadie, Brian
Won, Brian
Brisson, Ryan
Karrison, Theodore
Hensing, Thomas
Kozloff, Mark
Bao, Riyue
Patel, Jyoti D.
Luke, Jason J.
ONCOTARGET, 2018, 9 (04) : 4375 - 4384
[34] IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study
Yuan, Wenli
Deng, Deyao
Li, Hanyu
Hu, Xinghui
Shang, Xueqin
Hou, Xia
Jiang, Hongchao
He, Hongchun
ONCOTARGETS AND THERAPY, 2021, 14 : 3051 - 3062
[35] Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
Rao, Martin
Valentini, Davide
Dodoo, Ernest
Zumla, Alimuddin
Maeurer, Markus
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 56 : 221 - 228
[36] A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Nunes-Xavier, Caroline E.
Angulo, Javier C.
Pulido, Rafael
Lopez, Jose I.
CURRENT UROLOGY REPORTS, 2019, 20 (01)
[37] Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
Bulen, Benjamin J.
Khazanov, Nickolay A.
Hovelson, Daniel H.
Lamb, Laura E.
Matrana, Marc
Burkard, Mark E.
Yang, Eddy Shih-Hsin
Edenfield, William J.
Claire Dees, Elizabeth
Onitilo, Adedayo A.
Buchschacher, Gary L.
Miller, Alan M.
Parsons, Benjamin M.
Wassenaar, Timothy R.
Suga, Jennifer M.
Siegel, Robert D.
Irvin, William
Nair, Suresh
Slim, Jennifer N.
Misleh, Jamal
Khatri, Jamil
Masters, Gregory A.
Thomas, Sachdev
Safa, Malek M.
Anderson, Daniel M.
Mowers, Jonathan
Dusenbery, Anna C.
Drewery, Stephanie
Plouffe, Komal
Reeder, Travis
Vakil, Hana
Patrias, Lynnae
Falzetta, Amanda
Hamilton, Ryan
Kwiatkowski, Kat
Johnson, D. Bryan
Rhodes, Daniel R.
Tomlins, Scott A.
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (07): : 1335 - 1349
[38] Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma
Lin, Hansen
Fu, Liangmin
Li, Pengju
Zhu, Jiangquan
Xu, Quanhui
Wang, Yinghan
Mumin, Mukhtar Adan
Zhou, Xinwei
Chen, Yuhang
Shu, Guannan
Yao, Gaosheng
Chen, Minyu
Lu, Jun
Zhang, Lizhen
Liu, YuJun
Zhao, Yiqi
Bao, Jiahao
Chen, Wei
Luo, Junhang
Li, Xiaofei
Chen, Zhenhua
Cao, Jiazheng
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[39] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
Sui, Xinbing
Ma, Junhong
Han, Weidong
Wang, Xian
Fang, Yong
Li, Da
Pan, Hongming
Zhang, Li
ONCOTARGET, 2015, 6 (23) : 19393 - 19404
[40] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Jilkova, Zuzana Macek
Aspord, Caroline
Decaens, Thomas
CANCERS, 2019, 11 (10)

← 1 2 3 4 5 →